- Conditions
- Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
- Interventions
- bleomycin sulfate, doxorubicin hydrochloride, liposomal vincristine sulfate, vinorelbine tartrate, cyclophosphamide, etoposide phosphate, prednisone, filgrastim, ifosfamide
- Biological · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2022
- U.S. locations
- 156
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 121 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 5,300
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Ocular Infections, Irritations and Inflammations
- Interventions
- KPI-121 0.25%, KPI-121 1.0%, Vehicle of KPI-121 0.25%, Vehicle of KPI-121 1.0%
- Drug
- Lead sponsor
- Kala Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 23
- States / cities
- Artesia, California • Mission Hills, California • Rancho Cordova, California + 17 more
- Conditions
- Idiopathic Focal Segmental Glomerulosclerosis
- Interventions
- Acthar Gel
- Drug
- Lead sponsor
- Mallinckrodt ARD LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Chula Vista, California + 16 more
- Conditions
- Colorectal Cancer
- Interventions
- fluorouracil, irinotecan hydrochloride, conventional surgery, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 216
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 166 more
- Conditions
- Melanoma
- Interventions
- TKI258
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 3
- States / cities
- Louisville, Kentucky • Pittsburgh, Pennsylvania • Houston, Texas
- Conditions
- Multiple Sclerosis
- Interventions
- other disease-modifying therapy, Fingolimod
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 3,076 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 208
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 181 more
- Conditions
- Growth Hormone Deficiency
- Interventions
- Somatropin
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 3 Years to 14 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 33
- States / cities
- Little Rock, Arkansas • Orange, California • Sacramento, California + 28 more
- Conditions
- Breast Cancer
- Interventions
- Alpelisib, Fulvestrant, Letrozole, Goserelin, Leuprolide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 383 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 25
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Anaheim, California + 20 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Casdozokitug, Toripalimab, Bevacizumab
- Drug
- Lead sponsor
- Coherus Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 25
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Beverly Hills, California + 22 more
- Conditions
- Ovarian Carcinoma
- Interventions
- Bilateral Salpingectomy, Bilateral Salpingectomy with Oophorectomy, Biospecimen Collection, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Transvaginal Ultrasound, Ultrasound Imaging
- Procedure · Other
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 35 Years to 50 Years · Female only
- Enrollment
- 1,956 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2047
- U.S. locations
- 564
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 372 more
- Conditions
- Pterygium
- Interventions
- CBT-001, Vehicle
- Drug
- Lead sponsor
- Cloudbreak Therapeutics, LLC
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 660 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 20
- States / cities
- Dothan, Alabama • Sun City, Arizona • Bakersfield, California + 16 more
- Conditions
- Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Laboratory Biomarker Analysis, Leucovorin Calcium, Levoleucovorin, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Questionnaire Administration, Therapeutic Hydrocortisone, Thioguanine, Vincristine Sulfate
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 352 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2034
- U.S. locations
- 184
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 145 more
- Conditions
- Chalazion
- Interventions
- SUN-131 1.5% TDS, Placebo TDS
- Drug
- Lead sponsor
- Senju USA, Inc.
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 65
- States / cities
- Chandler, Arizona • Prescott, Arizona • Sun City, Arizona + 56 more
- Conditions
- Ovarian Cancer Recurrent
- Interventions
- EP-100, Paclitaxel
- Drug
- Lead sponsor
- Esperance Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 15
- States / cities
- Greenbrae, California • San Francisco, California • Louisville, Kentucky + 11 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- liraglutide, placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 9,341 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 125
- States / cities
- Alabaster, Alabama • Birmingham, Alabama • Huntsville, Alabama + 106 more
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- BI 770371, Pembrolizumab, Cetuximab
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- Louisville, Kentucky • Minneapolis, Minnesota • Columbus, Ohio
- Conditions
- Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma, Ovarian Cancer, Anogenital Cancers, HPV - Anogenital Human Papilloma Virus Infection, HPV-Related Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Malignancy, HPV-Related Adenocarcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Associated Vaginal Adenocarcinoma, HPV-Related Endocervical Adenocarcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Verrucous Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV Positive Rectal Squamous Cell Carcinoma
- Interventions
- TSC-204-A0201, TSC-204-C0702, TSC-200-A0201, TSC-204-A0201 + TSC-204-C0702, TSC-204-A0201 + TSC-200-A0201, TSC-204-C0702 + TSC-200-A0201, TSC-204-A0201 + TSC-203-A0201, TSC-204-C0702 + TSC-203-A0201, TSC-200-A0201 + TSC-203-A0201, TSC-203-A0201, TSC-204-A0101, TSC-201-B0702, TSC-204-A0201 + TSC-204-A0101, TSC-204-A0201 + TSC-201-B0702, TSC-204-C0702 + TSC-204-A0101, TSC-204-C0702 + TSC-201-B0702, TSC-200-A0201 + TSC-204-A0101, TSC-200-A0201 + TSC-201-B0702, TSC-203-A0201 + TSC-204-A0101, TSC-203-A0201 + TSC-201-B0702, TSC-202-A0201, TSC-204-A0201 + TSC-202-A0201, TSC-204-C0702 + TSC-202-A0201, TSC-200-A0201 + TSC-202-A0201, TSC-203-A0201 + TSC-202-A0201, TSC-204-A0101 + TSC-202-A0201, TSC-201-B0702 + TSC-202-A0201
- Biological
- Lead sponsor
- TScan Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 840 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 21
- States / cities
- Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 17 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Zanubrutinib, Ibrutinib
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 652 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 30
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Boulder, Colorado + 25 more
- Conditions
- Parapsoriasis
- Interventions
- Apremilast, Placebo, Placebo-Apremilast
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 221 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Fremont, California • Los Angeles, California + 21 more
- Conditions
- Head and Neck Neoplasms, Mucositis
- Interventions
- Brilacidin, Placebo
- Drug · Other
- Lead sponsor
- Innovation Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 16
- States / cities
- Gilbert, Arizona • Lakeland, Florida • Columbus, Georgia + 13 more
- Conditions
- Alopecia Areata
- Interventions
- Baricitinib, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 784 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 41 more
- Conditions
- Seasonal Allergic Conjunctivitis
- Interventions
- Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution, Ketotifen fumarate ophthalmic solution 0.035%, Brimonidine tartrate ophthalmic solution 0.025%, Experimental: Vehicle ophthalmic solution
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 6
- States / cities
- Louisville, Kentucky • Andover, Massachusetts • Goodlettsville, Tennessee + 3 more
- Conditions
- Multiple Myeloma
- Interventions
- Cilta-cel OOS Therapy
- Drug
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 137
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Goodyear, Arizona + 96 more
- Conditions
- Critical Illness, Sepsis, Multiple Organ Failure
- Interventions
- Glutamine, Antioxidants, Glutamine + Antioxidants, Placebo
- Other
- Lead sponsor
- Daren K. Heyland
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,223 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Louisville, Kentucky • Dayton, Ohio + 2 more